Panel Discussion: Venture Capital Investment in Early Stage Life Science Company

Panel Discussion: Venture Capital Investment in Early Stage Life Science Company
-This event is proudly hosted and co-sponsored by Baker Botts, LLP1
and co-sponsored by the New York City Bioscience Initiative2.

Lead panelists: Chau Khuong (OrbiMed), Will Shen (J&J) and Nick Wachtel (Lux Capital)
Venue: 44th Floor, 30 Rockefeller Plaza, New York, NY 10112
Time: 6:00pm – Thursday, November 6th

Topics to be covered:
· What are the investment strategies of life science venture capital firms?
· How does the current credit crunch affect investment in early stage life science companies?
· How can biotech entrepreneurs make deals with VC?
· Who should early stage life science companies talk to, corporate or VC firms?

About the lead panelists:
Chau Q. Khuong, Private Equity Principal, OrbiMed LLC. Mr. Khuong joined OrbiMed, which is the world's largest healthcare-dedicated investment firm with over $6 billion in assets under management, in 2003 to focus on biotechnology and medical device investments into both private equity and small capitalization public companies. Mr. Khuong holds a B.S. degree in Molecular, Cellular, and Developmental Biology (Concentration in Biotechnology) and a Master's in Public Health (Concentration in Infectious Disease), both from Yale University. He was actively involved in OrbiMed investments in Arius Research (acquired by Roche, 2008), Peninsula Pharmaceuticals (acquired by JNJ, 2005), Cerexa (acquired by Forest, 2007), Adiana (acquired by Cytyc, 2007), Biodel (NASDAQ: BIOD), and Emphasys Medical. Mr. Khuong currently serves on the Board of Directors at Cerapedics and is an Observer on the Board of Directors at Biolex, Glaukos, and Pieris AG.

Will Shen, Johnson & Johnson. Mr. Shen is a member of the biopharmaceutical investment team at Johnson & Johnson Development Corporation, the venture capital arm of J&J. He currently serves as a board observer of Optherion and also played a significant role in JJDC's investment in Catalyst Biosciences. Will received his MBA from the Wharton School of the University of Pennsylvania, focusing on Finance and Healthcare Management. At Wharton, Will worked closely with Penn's Center for Technology Transfer on the commercialization of a polymer-based nanoparticle technology. Will earned his PhD in Chemical Engineering from Stanford University. He completed his BS in Chemistry from the University of Florida.

Nick Wachtel, Lux Capital. Mr. Wachtel is an associate with Lux Capital, based in the firm's New York office. He joined Lux in early 2005 and focuses on early-stage investments in nanotechnology, biotechnology, and alternative energy. Nick has worked with Lux portfolio companies including Genocea, Magen, and Tempo Pharmaceuticals. Prior to joining Lux, he worked at Delta Group, a New York private equity firm. Nick received his B.B.A in Finance from Emory University's Goizueta Business School. Nick is one of the founders of Young Wall Street, a non-profit organization dedicated to improving the lives of New York City's youths and adolescents. Nick has been a featured speaker at a number of conferences and an invited lecturer on the topics of nanotechnology and venture capital at various universities including Cornell.

1Baker Botts L.L.P., dating from 1840, is a leading international law firm with offices in Austin, Beijing, Dallas, Dubai, Hong Kong, Houston, London, Moscow, New York, Palo Alto, Riyadh and Washington. With more than 800 lawyers, Baker Botts provides a full range of legal services to international, national and regional clients.

2New York City Bioscience Initiative is a private public partnership with New York City Economic Development Corporation, New York City Investment Fund, and Partnership for New York City, the city’s research institutions and members of the investment community